Although emerging cell- or animal-based evidence supports the relationship between SND1 and cancers, no pan-cancer analysis is available. We thus first explored the potential oncogenic roles of SND1 across thirty-three tumors based on the datasets of TCGA (The cancer genome atlas) and GEO (Gene expression omnibus). SND1 is highly expressed in most cancers, and distinct associations exist between SND1 expression and prognosis of tumor patients. We observed an enhanced phosphorylation level of S426 in several tumors, such as breast cancer or lung adenocarcinoma. SND1 expression was associated with the CD8⁺ T-cell infiltration level in colon adenocarcinoma and melanoma, and cancer-associated fibroblast infiltration was observed in other tumors, such as bladder urothelial carcinoma or testicular germ cell tumors. Moreover, protein processing- and RNA metabolism-associated functions were involved in the functional mechanisms of SND1. Our first pan-cancer study offers a relatively comprehensive understanding of the oncogenic roles of SND1 across different tumors.

尽管新出现的基于细胞或动物的证据支持 SND1 与癌症之间的关系，但尚无泛癌症分析可用。因此，我们首先基于 TCGA（癌症基因组图谱）和 GEO（基因表达综合）的数据集探索了 SND1 在 33 种肿瘤中的潜在致癌作用。SND1在大多数癌症中高度表达，SND1表达与肿瘤患者预后之间存在明显关联。我们观察到 S426 在几种肿瘤中的磷酸化水平增强，例如乳腺癌或肺腺癌。SND1表达与CD8 ⁺ T 细胞相关在结肠腺癌和黑色素瘤中的浸润水平，以及在其他肿瘤中观察到与癌症相关的成纤维细胞浸润，例如膀胱尿路上皮癌或睾丸生殖细胞肿瘤。此外，蛋白质加工和 RNA 代谢相关功能参与了 SND1 的功能机制。我们的第一项泛癌研究对 SND1 在不同肿瘤中的致癌作用提供了相对全面的理解。